No profile data available.
CorMedix Inc. (CRMD) is a healthcare company in the IV treatment equipment industry, based in Parsippany, United States, with about 191 full-time employees.
It reported revenue of $311.71 million for fiscal year 2025, up 617.0% from fiscal year 2024, and net income of $162.07 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $99.31 million, up 149.9% from a year before. Its market capitalization was $575.23 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.
CorMedix reported $311.71 million in revenue for fiscal year 2025, up 617.0% from $43.47 million in fiscal year 2024. In Q2 2026 revenue was $99.31 million.
$575.23 million as of October 9, 2026.
Listed companies of a similar size in the same industry (IV treatment equipment) include Tandem Diabetes Care, Inc. (TNDM), Iradimed Corporation (IRMD), Beta Bionics, Inc. (BBNX), Delcath Systems, Inc. (DCTH).